Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

11.3K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.3K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

215
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
215
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated quantification of skin Gb3 load and white matter lesion assessment in Fabry disease.

Orphanet journal of rare diseases·2026
Same author

Sedation early after return of spontaneous circulation and during pre-hospital transport after out-of-hospital cardiac arrest: retrospective analysis of the AfterROSC1 & 2 database.

Resuscitation·2026
Same author

Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.

Diabetes, obesity & metabolism·2026
Same author

Pharmacological treatment of cardiogenic shock.

Current opinion in critical care·2026
Same author

The American Society of ExtraCorporeal Technology Standards and Guidelines for Pediatric and Congenital Perfusion Practice: 2025 Update.

World journal for pediatric & congenital heart surgery·2026
Same author

Evaluating Four HIT Prediction Scores After Cardiac Surgery With Cardiopulmonary Bypass: A Comparative Study.

Journal of cardiothoracic and vascular anesthesia·2026

Related Experiment Video

Updated: Jul 26, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

Perspectives in weight control in diabetes - Survodutide.

Thomas Klein1, Robert Augustin1, Anita M Hennige2

  • 1Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany.

Diabetes Research and Clinical Practice
|June 17, 2023
PubMed
Summary

Survodutide, a dual glucagon/GLP-1 receptor agonist, shows promise for treating Type 2 diabetes and obesity. This novel peptide effectively lowers blood sugar and body weight, offering greater efficacy than GLP-1R agonists alone.

Keywords:
Diabetes Mellitus, Type 2Glucagon-Like Peptide 1IncretinsObesity managementReceptors, Glucagon

More Related Videos

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice
08:50

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Published on: October 18, 2024

627
Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.0K

Related Experiment Videos

Last Updated: Jul 26, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K
Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice
08:50

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Published on: October 18, 2024

627
Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.0K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Glucagon-like peptide-1 receptor (GLP-1R) agonists are established treatments for Type 2 diabetes mellitus (T2DM) and obesity.
  • Oxyntomodulin, a natural hormone, weakly activates both the glucagon receptor (GCGR) and GLP-1R.
  • Dual agonism targeting GCGR and GLP-1R represents a therapeutic advancement for T2DM and obesity.

Purpose of the Study:

  • To evaluate the efficacy and potential of survodutide, a novel dual GCGR/GLP-1R agonist, in patients with T2DM and obesity.
  • To assess the glucose-lowering and body weight-reducing effects of survodutide compared to existing therapies.

Main Methods:

  • Survodutide is a 29-amino acid peptide derived from glucagon, modified with GLP-1 activities and a C18 diacid for albumin binding.
  • Albumin binding extends survodutide's half-life, enabling once-weekly subcutaneous administration.
  • The study involved a Phase II clinical trial in patients diagnosed with T2DM and obesity.

Main Results:

  • Survodutide demonstrated significant glucose-lowering efficacy, reducing glycated haemoglobin levels.
  • Clinically meaningful body weight loss was observed in participants treated with survodutide.
  • The dual GCGR/GLP-1R agonism of survodutide showed enhanced therapeutic effects compared to GLP-1R agonism alone.

Conclusions:

  • Dual GCGR/GLP-1R agonism, as exemplified by survodutide, holds significant potential for managing T2DM and obesity.
  • Survodutide offers a promising therapeutic strategy for improving glycemic control and promoting weight loss.
  • This approach may provide superior efficacy over therapies targeting only the GLP-1R pathway.